TGen, Lilly scientists' discovery of gene mutation could be cancer breakthrough

This could have a huge impact on cancer treatment and drug development, said Jeff Trent, scientific director at TGen.

"This has remarkably the potential to be one of the most important studies in cancer in the last decade," Trent said. "This is going to be one of those models where a genetic change -- recognized, proven and validated -- is going to have the possibility for important clinical use in an accelerated period of time.

"It demonstrates the importance of studying the genetic makeups of these cancers."

The discovery could help researchers develop and target specific drugs to best treat different kinds of cancer. In essence, it could help doctors create personalized medicine for cancer patients, tailoring drugs to the genetic makeup of each patient.

"This is a classic example of why we're investing into the biosciences and the type of return we can get," said Jon McGarity, past president and chief executive of Arizona BioIndustry Association. "This is a giant step forward."

John Murphy, president and chief executive of The Flinn Foundation, said TGen continues to make profound contributions to the international scientific community.

"These discoveries, plus collaborations with leading pharmaceutical firms such as Lilly, are helping to place Arizona on the bioscience map," Murphy said.

About two years ago, TGen set up a cooperative research and development agreement with Eli Lilly so they could work together to study the genetic makeup of cancer.

source : www.bizjournals.com